Skip to main content
SpringerLink
Log in

Measuring the Effects of Medication for Individuals with Autism

  • Chapter
  • First Online:
Handbook of Parent-Child Interaction Therapy for Children on the Autism Spectrum

  • 2457 Accesses

Abstract

Psychotropic medication is often prescribed for individuals with autism spectrum disorders (ASD) for a variety of behavioral concerns. These concerns can include problem behaviors such as aggression, self-injury, or property destruction, as well as repetitive and compulsive behavior. Other concerns such as impulsivity, inattentiveness, and mood disturbances may also be targeted by psychotropic medication. Unfortunately, medical providers often have to rely on caregivers to report changes in behavioral outcomes rather than gathering the information directly from the person taking the medication. Thus, the goal of this chapter is to help guide clinicians and educators to work collaboratively with medical providers to assist in measuring the effects of medications on the behavior targeted. In addition, information on collateral effects of the medication on other behaviors as well as side effects of medication can be monitored. Information on the drug development process, physiological measures that can be used to assess therapeutic outcomes, and tools for clinicians and families to use to measure medication effects are also described. Finally, guidelines for enhancing collaboration between patients, families, educators, and providers on treatment plan development are emphasized.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 429.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Allen, M. H., Hirschfeld, R. M., Wozniak, P. J., Baker, J. D., & Bowden, C. L. (2006). Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. American Journal of Psychiatry, 163(2), 272–275.

    Article  PubMed  Google Scholar 

  • Alter, P. J., Conroy, M. A., Mancil, G., & Haydon, T. (2008). A comparison of functional behavior assessment methodologies with young children: Descriptive methods and functional analysis. Journal of Behavioral Education, 17(2), 200–219.

    Article  Google Scholar 

  • Aman, M., Novotny, S., Samango-Sprouse, C., Lecavalier, L., Leonard, E., Gadow, K., … Chez, M. (2004). Outcome measures for clinical drug trials in autism. CNS Spectrums, 9(1), 36–47. https://doi.org/10.1017/S1092852900008348

    Article  PubMed  PubMed Central  Google Scholar 

  • Aman, M. G. (2012a). Aberrant Behavior Checklist: Current identity and future developments. Journal of Clinical and Experiment Pharmacology, 2, e114. https://doi.org/10.4172/2161-1459.1000e114

    Article  Google Scholar 

  • Aman, M.G. (2012b, June) Annotated biography on the Aberrant Behavior Checklist (ABC). Unpublished Manuscript. Columbus, OH: The Ohio State University.

    Google Scholar 

  • Aman, M. G., Alvarez, N., Benefield, W., Crismon, M. L., Green, G., King, B. H., … Szymanski, L. (2002). Treatment of psychiatric and behavioral problems in mental retardation. American Journal on Mental Retardation, 105, 159–228.

    Google Scholar 

  • Aman, M. G., Burrow, W. H., & Wolford, P. L. (1995). The Aberrant Behavior Checklist—Community: Factor validity and effect of subject variables for adults in group homes. American Journal on Mental Retardation, 100, 283–292.

    PubMed  Google Scholar 

  • Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., … Sukhodolsky, D. D. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child & Adolescent Psychiatry, 48(12), 1143–1154.

    Article  Google Scholar 

  • Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.

    Google Scholar 

  • Aman, M. G., Tassé, M. J., Rojahn, J., & Hammer, D. (1996). The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities, 17, 41–57.

    Article  PubMed  Google Scholar 

  • Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Shell, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal of Autism and Developmental Disorders, 19(2), 227–239. https://doi.org/10.1007/BF02211843

    Article  PubMed  Google Scholar 

  • Arnold, L. E. (1993). Clinical pharmacological issues in treating psychiatric disorders of patients with mental retardation. Annals of Clinical Psychiatry, 5(3), 189–197.

    Article  PubMed  Google Scholar 

  • Arnold, L. E., Aman, M. G., Cook, A. M., Witwer, A. N., Hall, K. L., Thompson, S., & Ramadan, Y. (2006). Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45(10), 1196–1205.

    Article  PubMed  Google Scholar 

  • Arnold, L. E., Aman, M. G., Martin, A., Collier-Crespin, A., Vitiello, B., Tierney, E., … Klin, A. (2000). Assessment in multisite randomized clinical trials of patients with autistic disorder: The Autism RUPP Network. Journal of Autism and Developmental Disorders, 30(2), 99–111.

    Article  PubMed  Google Scholar 

  • Ballinger, C. T., Varley, C. K., & Nolen, P. A. (1984). Effects of methylphenidate on reading in children with ADD. American Journal of Psychiatry, 141, 1590–1593.

    Article  PubMed  Google Scholar 

  • Barkley, R. A., McMurray, M. B., Edelbrock, C. S., & Robbins, K. (1990). Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systemic, placebo-controlled evaluation. Pediatrics, 86(2), 184–192.

    PubMed  Google Scholar 

  • Benedetto-Nasho, E., & Tannock, R. (1999). Math computation performance and error patterns of children with attention deficit hyperactivity disorder. Journal of Attention Disorders, 3, 121–134.

    Article  Google Scholar 

  • Biederman, J., Mick, E., Faraone, S. V., Wozniak, J., Spencer, T., & Pandina, G. (2006). Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: A post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study. Clinical Therapy, 28, 794–800.

    Article  Google Scholar 

  • Brass, E. P. (2010). The gap between clinical trials and clinical practice: The use of pragmatic clinical trials to inform regulatory decision making. Clinical Pharmacology & Therapeutics, 87(3), 351–355.

    Article  Google Scholar 

  • Buchsbaum, M., Hollander, E., Haznedar, M., Tong, C., Spiegal-Cohen, J., Wei, T., … Cartwright, C. (2001). Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: A pilot study. International Journal of Neuropsychopharmacology, 4(2), 119–125.

    Article  PubMed  Google Scholar 

  • Buitelaar, J. K., van der Gaag, R. J., Cohen-Kettenis, P., & Melman, C. T. (2001). A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with sub average cognitive abilities. The Journal of Clinical Psychiatry, 64(2), 239–248.

    Article  Google Scholar 

  • Busner, J., & Targum, S. D. (2007). The clinical global impressions scale. Psychiatry, 4(7), 28–37.

    PubMed  PubMed Central  Google Scholar 

  • Carlson, G., Pokrzywinski, J., Uran, K., & Valdovinos, M. (2012). The use of reinforcer assessments in evaluating psychotropic medication effects. Journal of Developmental and Physical Disabilities, 24, 515–528.

    Article  Google Scholar 

  • Cooper, J. O., Heron, T. E., & Heward, W. L. (2007). Applied behavior analysis. Upper Saddle River, NJ: Pearson/Merrill – Prentice Hall.

    Google Scholar 

  • Danvo, S. E., Tervo, R., Meyers, S., & Symons, F. J. (2012). Using functional analysis methodology to evaluate effects of an atypical antipsychotic on severe problem behavior. Journal of Mental Health Research in Intellectual Disabilities, 5, 286–308.

    Article  Google Scholar 

  • de Kuijper, G. M., & Hoekstra, P. J. (2017). Physician’s reasons on long-term use of antipsychotics. Journal of Intellectual Disability Research, 61(10), 899–908.

    Article  PubMed  Google Scholar 

  • Edelbrock, C. S. (1985). Child behavior rating form. Psychopharmacology Bulletin, 21, 835–837.

    Google Scholar 

  • Farmer, C., & Aman, M. G. (2017). Aberrant behavior checklist. Encyclopedia of Autism Spectrum Disorders, 1–8.

    Google Scholar 

  • FDA (February 1, 2016). What is a serious adverse event? Retrieved from: https://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm.

  • Findling, R. L., Aman, M. G., Eerdekens, M., Derivan, A., Llyons, B., & The Risperidone Disruptive Behavior Study Group. (2004). Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. The American Journal of Psychiatry, 161(4), 677–684.

    Article  PubMed  Google Scholar 

  • Findling, R. L., Reed, M. D., O’Riordan, M. A., Demeter, C. A., Stansbrey, R. J., & McNamara, N. K. (2006). Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 792–800.

    Article  PubMed  Google Scholar 

  • Findling, R. L., Reed, M. D., O’Riordan, M. A., Demeter, C. A., Stansbrey, R. J., & McNamara, N. K. (2007). A 26-week open-label study of quetiapine in children with conduct disorder. Journal of Child and Adolescent Psychopharmacology, 17, 1–9.

    Article  PubMed  Google Scholar 

  • Gagliano, A., Germano, E., Pustorino, G., Impallomeni, C., D’Arrigo, C., Calamoneri, F., & Spina, E. (2004). Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications. Journal of Child and Adolescent Psychopharmacology, 14(1), 39–47.

    Article  PubMed  Google Scholar 

  • Goodman, W. K., Price, L. H., Rasmussen, S. A., Mazure, C., Fleischmann, R. L., Hill, C. L., … Charney, D. S. (1989). The Yale–Brown obsessive compulsive scale: I. Development, use, and reliability. Archives of General Psychiatry, 46, 1006–1011.

    Article  PubMed  Google Scholar 

  • Goodman, W. K., Rasmussen, S. A., Price, L. H., & Storch, E. A. (2006). Yale–Brown obsessive-compulsive scale—Second Edition. Unpublished manuscript.

    Google Scholar 

  • Gordon, C. T., State, R. C., & Nelson, J. E. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50(6), 441–447. https://doi.org/10.1001/archpsyc.1993.01820180039004

    Article  PubMed  Google Scholar 

  • Guy, W. (1976). ECDEU Assessment manual for psychopharmacology, revised, 1976 (pp. 76–338). Rockville, MD: United States Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration.

    Google Scholar 

  • Hage, A., Banaschewski, T., Buitlaar, J. K., Dijkhuizen, R. M., Franke, B., Lythgoe, D. J., … TACTICS Consortium. (2016). Glutamatergic medication in the treatment of obsessive compulsive disorder and autism spectrum disorder- study protocol for a randomized controlled trial. Trials, 17(141), 1–16.

    Google Scholar 

  • Handen, B. L., Aman, M. G., Arnold, L. E., Hyman, S. L., Tumuluru, R. V., Lecavalier, L., … Silverman, L. B. (2015). Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 54(11), 905–915.

    Article  Google Scholar 

  • Handen, B. L., Johnson, C. R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30(3), 245–255.

    Article  PubMed  Google Scholar 

  • Hastings, R. P., Brown, T., Mount, R. H., & Cormack, K. F. M. (2001). Exploration of psychometric properties of the developmental behavior checklist. Journal of Autism and Developmental Disorders, 31(4), 423–431. https://doi.org/10.1023/A:1010668703948

    Article  PubMed  Google Scholar 

  • Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., … Cook, E. H. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child & Adolescent Psychopharmacology, 15(4), 682–692.

    Article  Google Scholar 

  • Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., & Iyengar, R. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30(3), 582–589.

    Article  PubMed  Google Scholar 

  • Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., … Settipani, B. A. (2012). A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry, 169(3), 292–299.

    Article  PubMed  Google Scholar 

  • Houghton, R., Ong, R. C., & Bolognani, F. (2017). Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States. Autism Research, 10, 2037–2047. https://doi.org/10.1002/aur.1848

    Article  PubMed  Google Scholar 

  • Iwata, B. A., Dorsey, M. F., Slifer, K. J., Bauman, K. E., & Richman, G. S. (1994). Toward a functional analysis of self-injury. Journal of Applied Behavior Analysis, 27, 197–209.

    Article  PubMed  PubMed Central  Google Scholar 

  • Johnson, C. R., Handen, B. L., Butter, E., Wagner, A., Mulick, J., Sukhodolsky, D. G., … Scahill, L. (2007). Development of a parent training program for children with pervasive developmental disorders. Behavior Intervention, 22, 201–221.

    Article  Google Scholar 

  • Johnston, J. M., Pennypacker, H. S., & Green, G. (2010). Strategies and tactics of behavioral research. Abingdon-on-Thames, UK: Routledge.

    Google Scholar 

  • Kaat, A. J., Lecavalier, L., & Aman, M. G. (2014). Validity of the aberrant behavior checklist in children with autism spectrum disorder. Journal of Autism Developmental Disorders, 44(5), 1103–1116. https://doi.org/10.1007/s10803-013-1970-0

    Article  PubMed  Google Scholar 

  • Kalachnik, J. E. (1999). Measuring side effects of psychopharmacologic medication in individuals with mental retardation and developmental disabilities. Developmental Disabilities Research Reviews, 5(4), 348–359.

    Article  Google Scholar 

  • Kalachnik, J. E., & Sprague, R. L. (1993). The Dyskinesia Identification System Condensed User Scale (DISCUS): Reliability, validity, and a total cut-off for mentally ill and mentally retarded populations. Journal of Clinical Psychology, 49, 177–189.

    PubMed  Google Scholar 

  • Karabekiroglu, K., & Aman, M. (2008). Validity of the aberrant behavior checklist in a clinical sample of toddlers. Child Psychiatry and Human Development, 40, 99–110. https://doi.org/10.1007/s10578-008-0108-7

    Article  PubMed  Google Scholar 

  • Kearney, A. J. (2008). Understanding applied behavior analysis: An introduction to ABA for parents, teachers, and other professionals. Philadelphia: Jessica Kingsley Publishers.

    Google Scholar 

  • King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., … Ritz, L. (2009). Lack of efficacy in citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583–590. https://doi.org/10.1001/archgenpsychiatry.2009.30

    Article  PubMed  PubMed Central  Google Scholar 

  • Klotz, U. (2007). The role of pharmacogenetics in the metabolism of antiepileptic drugs. Clinical Pharmacokinetics, 46(4), 271–279.

    Article  PubMed  Google Scholar 

  • Langworthy-Lam, K. S., Aman, M. G., & Van Bourgondien, M. E. (2002). Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology, 12(4), 311–321.

    Article  PubMed  Google Scholar 

  • LaRue, R. H., Northup, J., Baumeister, A. A., Hawkins, M. F., Seale, L., Williams, T., & Ridgway, A. (2008). An evaluation of stimulant medication on the reinforcing effects of play. Journal of Applied Behavior Analysis, 41, 143–147.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lecavalier, L., Aman, M. G., Hammer, D., Stocia, W., & Mathews, G. L. (2004). Factor analysis of the Nisonger Child Behavior Rating Scale Form in children with autism spectrum disorders. Journal of Autism and Developmental Disorders, 34(6), 709–721.

    Article  PubMed  Google Scholar 

  • Ledford, J. R., Lane, J. D., & Gast, D. L. (2018). Dependent variables, measurement, and reliability. In J. R. Ledford & D. L. Gast (Eds.), Single case research methodology: Applications in special education and behavioral sciences (3rd ed., pp. 97–132). New York, NY: Routledge.

    Chapter  Google Scholar 

  • LoVullo, S. V., & Matson, J. L. (2009). Comorbid psychopathology in adults with autism spectrum disorders in intellectual disabilities. Research in Developmental Disabilities, 30, 1288–1296.

    Article  PubMed  Google Scholar 

  • Madsen, E. K., Peck, J. A., & Valdovinos, M. G. (2016). A review of research on direct-care staff data collection regarding the severity and function of challenging behavior in individuals with intellectual and developmental disabilities. Journal of Intellectual Disabilities, 20, 296–306.

    Article  PubMed  Google Scholar 

  • Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008). Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121(3), e441–e448.

    Article  PubMed  Google Scholar 

  • Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, M. G. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 48(11), 1110–1119.

    Article  Google Scholar 

  • Marshburn, E. C., & Aman, M. (1992). Factor validity norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. Journal of Autism and Developmental Disorders, 22, 357–373. https://doi.org/10.1007/BF01048240

    Article  PubMed  Google Scholar 

  • Matson, J., & Neal, D. (2009). Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview. Research in Developmental Disabilities, 30, 572–586.

    Article  PubMed  Google Scholar 

  • Matson, J. L., & Mahan, S. (2010). Antipsychotic drug side effects for persons with intellectual disability. Research in Developmental Disabilities, 31(6), 1570–1576.

    Article  PubMed  Google Scholar 

  • Matson, J. L., Mayville, E. A., Bielecki, J., Barnes, W. H., Bamburg, J. W., & Baglio, C. S. (1998). Reliability of the Matson evaluation of drug side effects scale (MEDS). Research in Developmental Disabilities, 19(6), 501–506.

    Article  PubMed  Google Scholar 

  • McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., … McDougle, C. J. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314–321.

    Article  PubMed  Google Scholar 

  • McDougle, C., Naylor, S., Cohen, D., Volkmar, F., Heninger, G., & Price, L. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53(11), 1001–1008.

    Article  PubMed  Google Scholar 

  • McDougle, C. J., Holmes, J. P., Bronson, M. R., Anderson, G. M., Volkmar, F. R., Price, L. H., & Cohen, D. (1997). Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of American Academy of Child and Adolescent Psychiatry, 36, 685–693.

    Article  Google Scholar 

  • McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., … Shah, B. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry, 162(6), 1142–1148.

    Article  PubMed  Google Scholar 

  • Meyer, U. A. (2000). Pharmacogenetics and adverse drug reactions. The Lancet, 356(9242), 1667–1671.

    Article  Google Scholar 

  • Mills, E. J., Chan, A. W., Wu, P., Vail, A., Guyatt, G. H., & Altman, D. G. (2009). Design, analysis, and presentation of crossover trials. Trials, 10(1), 27.

    Article  PubMed  PubMed Central  Google Scholar 

  • Napolitano, D. A., Jack, S. L., Sheldon, J. B., Williams, D. C., McAdam, D. B., & Schroeder, S. R. (1999). Drug-behavior interactions in persons with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5(4), 322–334.

    Article  Google Scholar 

  • Nicolson, R., Awad, G., & Sloman, L. (1998). An open trial of risperidone in young children with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 37(4), 372–376. https://doi.org/10.1097/00004583-199804000-00014

    Article  PubMed  Google Scholar 

  • Overall, J. E., & Campbell, M. (1988). Behavioral assessment of psychopathology in children: Infantile autism. Journal of Clinical Psychology, 44(5), 708–716.

    Article  PubMed  Google Scholar 

  • Overall, J. E., & Pfefferbaum, B. (1984). A brief scale for rating psychopathology in children. Innovations in Clinical Practice: A Source Book, 3, 257–266.

    Google Scholar 

  • Owen, R., Sikich, l., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., … Findling, R. L. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124(6), 1533–1540. https://doi.org/10.1542/peds.2008-3782

    Article  PubMed  Google Scholar 

  • Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007). Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 37(2), 367–373.

    Article  PubMed  Google Scholar 

  • Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine, 347, 314–321.

    Article  Google Scholar 

  • Reyes, M., Croonenberghs, J., Augustyns, I., & Eerdekens, M. (2006). Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. Journal of Child and Adolescent Psychopharmacology, 16, 260–272.

    Article  PubMed  Google Scholar 

  • Robinson, J. (2013). Children’s psychiatric rating scale. In F. R. Volkmar (Ed.), Encyclopedia of autism spectrum disorders. New York, NY: Springer. https://doi.org/10.1007/978-1-4419-1698-3

    Chapter  Google Scholar 

  • Rojahn, J., Rowe, E. W., Macken, J., Gray, A., Delitta, D., Booth, A., & Kimbrell, K. (2010). Psychometric evaluation of the Behavior Problems Inventory-01 and the Nisonger Child Behavior Rating Form with children and adolescents. Journal of Mental Health Research in Intellectual Disabilities, 3(1), 28–50. https://doi.org/10.1080/19315860903558168

    Article  Google Scholar 

  • Scahill, L., McDougle, C. J., Aman, M. G., Johnson, C., Handen, B., Bearss, K., … Stigler, K. A. (2012). Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems. Journal of the American Academy of Child & Adolescent Psychiatry, 51(2), 136–146.

    Article  Google Scholar 

  • Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., Goodman, W. K., … Leckman, J. F. (1997). Children’s Yale-Brown obsessive compulsive scale: Reliability and validity. Journal of American Academy of Child and Adolescent Psychiatry, 36, 844–852.

    Article  Google Scholar 

  • Schall, C. (2002). A consumer’s guide to monitoring psychotropic medication for individuals with autism spectrum disorders. Focus on Autism and Other Developmental Disabilities, 17(4), 229–235.

    Article  Google Scholar 

  • Schroeder, S. R., Hellings, J. A., & Courtemanche, A. B. (2013). How to make effective evaluation of psychotropic drug effects in people with developmental disabilities and self-injurious behavior. In Handbook of crisis intervention and developmental disabilities (pp. 299–316). New York: Springer.

    Chapter  Google Scholar 

  • Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., & Dunbar, F. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634–e641.

    Article  PubMed  Google Scholar 

  • Sibley, M. H., Kuriyan, A. B., Evans, S. W., Waxmonsky, J. G., & Smith, B. H. (2014). Pharmacological and psychosocial treatments for adolescents with ADHD: An updated systematic review of the literature. Clinical Psychology Review, 34(3), 218–232.

    Article  PubMed  Google Scholar 

  • Singh, N. N., Singh, A. N., Lancioni, G. E., & Adkins, A. D. (2010). Pharmacological adjuncts. In Handbook of clinical psychology competencies (pp. 1619–1653). New York, NY: Springer.

    Google Scholar 

  • Sleister, H. M., & Valdovinos, M. G. (2011). Why research on the pharmacogenetics of atypical antipsychotic-induced weight gain in individuals with intellectual disabilities is warranted. Journal of Mental Health Research in Intellectual Disabilities, 4(2), 65–78.

    Article  Google Scholar 

  • Smith, T., Sharp, S., Manzardo, A. M., & Butler, M. G. (2015). Pharmacogenetics informed decision making in adolescent psychiatric treatment: A clinical case report. International Journal of Molecular Sciences, 16(3), 4416–4428.

    Article  PubMed  PubMed Central  Google Scholar 

  • Snyder, R., Turgay, A., Aman, M., Binder, C., Fisman, S., & Carroll, A. (2002). Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of the American Academy of Child & Adolescent Psychiatry, 41, 1026–1036.

    Article  Google Scholar 

  • Sprague, R. L., & Werry, J. S. (1971). Methodology of psychopharmacological studies with the retarded. International Review of Research in Mental Retardation, 5, 147–219.

    Article  Google Scholar 

  • Storch, E. A., Rasmussen, S. A., Price, L. H., Larson, M. J., Murphy, T. K., & Goodman, W. K. (2010). Development and psychometric evaluation of the Yale-Brown obsessive-compulsive scale-second edition. Psychological Assessment, 22(2), 223–232.

    Article  PubMed  Google Scholar 

  • Stortz, J. N., Lake, J. K., Cobigo, V., Ouellette-Kuntz, H. M., & Lunsky, Y. (2014). Lessons learned from our elders: How to study polypharmacy in populations with intellectual and developmental disabilities. Intellectual and Developmental Disabilities, 52(1), 60–77.

    Article  PubMed  Google Scholar 

  • Straetmans, J. M., van Schrojenstein Lantman-de, H. M., Schellevis, F. G., & Dinant, G. J. (2007). Health problems of people with intellectual disabilities: The impact for general practice. British Journal of General Practice, 57(534), 64–66.

    Google Scholar 

  • Tasse, J. M., Aman, M. G., Hammer, D., & Rojhan, J. (1996). The Nisonger Child Behavior Rating Form: Age and gender effects and norms. Research in Developmental Disabilities, 17(1), 59–75.

    Article  PubMed  Google Scholar 

  • Thompson, T., Zarcone, J., & Symons, F. (2004). Methodological issues in psychopharmacology for individuals with intellectual and developmental disabilities. In E. Emerson, C. Hatton, T. Parmeter, & T. Thompson (Eds.), International handbook of applied research in intellectual disabilities (pp. 549–580). Chichester: Wiley.

    Chapter  Google Scholar 

  • Tsai, L. Y. (2000). Children with autism spectrum disorder: Medicine today and in the new millennium. Focus on Autism and Other Developmental Disabilities, 15, 138–145.

    Article  Google Scholar 

  • Turgay, A., Binder, C., Snyder, R., & Fisman, S. (2002). Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics, 110(3), 1–12.

    Article  Google Scholar 

  • Unwin, G. L., & Deb, S. (2011). Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: A systematic review. Research in Developmental Disabilities, 32, 2121–2133.

    Article  PubMed  Google Scholar 

  • US Food and Drug Administration (2017). Precision medicine initiative. Retrieved January 4, 2018 from https://www.fda.gov/ScienceResearch/SpecialTopics/PrecisionMedicine/default.htm

  • Valdovinos, M. G., Henninger-McMahon, M., Schieber, E., Beard, L., & Haas, A. (2016). Assessing the impact of psychotropic medication changes on challenging behavior of individuals with intellectual disabilities. International Journal of Developmental Disabilities, 62, 200–211.

    Article  PubMed  Google Scholar 

  • Valdovinos, M. G., Nelson, S. M., Kuhle, N. L., & Dierks, A. M. (2009). Using analogue functional analysis to measure variations in problem behavior rate and function after psychotropic medication changes: A clinical demonstration. Journal of Mental Health Research in Intellectual Disabilities, 2, 279–293.

    Article  Google Scholar 

  • Van Bellinghen, M., & De Troch, C. (2001). Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology, 11, 5–13.

    Article  PubMed  Google Scholar 

  • Van der Oord, S., Prins, P. J., Oosterlaan, J., & Emmelkamp, P. M. (2008). Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: A meta-analysis. Clinical Psychology Review, 28(5), 783–800.

    Article  PubMed  Google Scholar 

  • Volkmar, F., Siegel, M., Woodbury-Smith, M., King, B., McCracken, J., & State, M. (2014). Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 53(2), 237–257.

    Article  Google Scholar 

  • Wasserman, S., Iyendar, R., Chaplin, W. F., Watner, D., Waldoks, S. E., Anagnostuo, E., … Hollander, E. (2006). Levetiracetam versus placebo in childhood and adolescent autism: A double-blind placebo-controlled study. International Clinical Psychopharmacology, 21, 363–3667.

    Article  PubMed  Google Scholar 

  • Wu, M. S., McGuire, J. F., Arnold, E. B., Lewin, A. B., Murphy, T. K., & Storch, E. A. (2014). Psychometric properties of the Children’s Yale-Brown obsessive compulsive scale in youth with autism spectrum disorders and obsessive-compulsive symptoms. Child Psychiatry and Human Development, 45, 201–211.

    Article  PubMed  Google Scholar 

  • Zarcone, J., Napolitano, D., & Valdovinos, M. (2008). Measurement of problem behavior during medication evaluations. Journal of Intellectual Disability Research, 52(12), 1015–1028.

    Article  PubMed  Google Scholar 

  • Zarcone, J. R., Hellings, J. A., Crandall, K., Reese, R. M., Marquis, J., Fleming, K., … Schroeder, S. R. (2001). Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. American Journal on Mental Retardation, 106(6), 525–538.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. May Institute, Randolph, MA, USA

    Jennifer Zarcone

  2. The Chicago School of Professional Psychology, Chicago, IL, USA

    Annette Griffith & Chrystal Jansz Rieken

Authors
  1. Jennifer Zarcone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annette Griffith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chrystal Jansz Rieken
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer Zarcone .

Editor information

Editors and Affiliations

  1. Department of Psychology, West Virginia University, Morgantown, WV, USA

    Cheryl Bodiford McNeil

  2. Department of Psychology, West Virginia University, Morgantown, WV, USA

    Lauren Borduin Quetsch

  3. National Autism Center, May Institute, Randolph, MA, USA

    Cynthia M. Anderson

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zarcone, J., Griffith, A., Rieken, C.J. (2018). Measuring the Effects of Medication for Individuals with Autism. In: McNeil, C., Quetsch, L., Anderson, C. (eds) Handbook of Parent-Child Interaction Therapy for Children on the Autism Spectrum. Springer, Cham. https://doi.org/10.1007/978-3-030-03213-5_5

Download citation

Publish with us

Policies and ethics

Search

Navigation